Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation
Retrieved on:
수요일, 8월 16, 2023
Graft-versus-host disease, System, University, Acute radiation syndrome, Nature, ARS, Marketing, Cellular, University of Kansas Health System, HCT, Pluri Inc., Cell, PLUR, Cytopenia, Regeneration, Patient, University of Kansas Medical Center, TASE, Blood, Vein graft failure, NIAID, Placentalia, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Vaccine, Pharmaceutical industry
As described in the article, in a successful Phase I first-in-human study which achieved its primary endpoint, patients with incomplete hematopoietic recovery post-hematopoietic cell transplantation (HCT) were treated with escalating doses of Pluri’s cell therapy, PLX-R18.
Key Points:
- As described in the article, in a successful Phase I first-in-human study which achieved its primary endpoint, patients with incomplete hematopoietic recovery post-hematopoietic cell transplantation (HCT) were treated with escalating doses of Pluri’s cell therapy, PLX-R18.
- Low levels of blood cells (cytopenia) post-HCT can persist despite adequate engraftment of donor cells.
- Pluri’s PLX-R18 cells secrete a large array of hematopoietic factors which promote regeneration, maturation, and differentiation of hematopoietic cells and stimulate their migration to peripheral blood.
- As a groundbreaking, first-in-class solution, PLX-R18’s capacity to augment hematopoietic system recovery and effectively manage diverse cytopenia holds immense promise.”